首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >Bronchiolitis obliterans in chronic graft-versus-host disease: Analysis of risk factors and treatment outcomes.
【24h】

Bronchiolitis obliterans in chronic graft-versus-host disease: Analysis of risk factors and treatment outcomes.

机译:慢性移植物抗宿主病中的闭塞性细支气管炎:危险因素和治疗结果的分析。

获取原文
获取原文并翻译 | 示例
           

摘要

Bronchiolitis obliterans (BrOb), a late complication of bone marrow transplantation (BMT), is associated with chronic graft-versus-host disease (GVHD) and is frequently fatal. To identify the risk factors associated with BrOb, the factors affecting survival, treatment outcomes, and causes of death of patients with BrOb, we retrospectively analyzed 2859 BMT recipients. No cases of BrOb occurred among 1070 autologous BMT recipients. Among 1789 allogeneic BMT recipients, we identified 47 patients with BrOb. In multivariate analysis, older recipients or donors and acute GVHD were significantly associated with the development of BrOb. Among patients with BrOb, 5-year survival from the time of transplantation was only 10%, versus 40% among allogeneic BMT recipients without BrOb. The clinical course of BrOb had a significant effect on survival: 79% survived 5 years from the time of BrOb diagnosis if BrOb improved versus 13% if there was no improvement after the first-line therapy. Predictors of response included older donors and recipients, a previous diagnosis of chronic GVHD, and diagnosis of BrOb 6 months after transplantation; each of these significantly increased the likelihood of a favorable response to treatment. BrOb had high mortality rate of 55%, and pulmonary failure was the leading cause of death. More effective BrOb therapy is needed, especially for patients with unfavorable presentation.
机译:闭塞性细支气管炎(BrOb)是骨髓移植(BMT)的晚期并发症,与慢性移植物抗宿主病(GVHD)相关,并且通常是致命的。为了确定与BrOb相关的危险因素,影响存活率,治疗结果和BrOb患者死亡原因的因素,我们回顾性分析了2859名BMT接受者。在1070名自体BMT接受者中未发生BrOb病例。在1789名异基因BMT接受者中,我们鉴定出47例BrOb患者。在多变量分析中,年龄较大的接受者或供体和急性GVHD与BrOb的发生密切相关。在患有BrOb的患者中,自移植之日起的5年生存率仅为10%,而在没有BrOb的异基因BMT接受者中,这一比例为40%。 BrOb的临床过程对生存率有显着影响:如果BrOb改善,则从BrOb诊断之日起5年内可存活79%,而在一线治疗后如果没有改善,则可存活13%。反应的预测因素包括较年长的供体和受体,先前诊断为慢性GVHD以及移植后6个月诊断为BrOb。这些都显着增加了对治疗产生良好反应的可能性。 BrOb的死亡率高达55%,而肺衰竭是导致死亡的主要原因。需要更有效的BrOb治疗,特别是对于表现不佳的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号